Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A recent study has investigated whether ezogabine, an anticonvulsant drug given to people with epilepsy, is affective for people with depression.

A woman holding a glass of water in one hand and putting a pill in her mouth with the other © Shutterstock

The study looked at how ezogabine affects certain brain activities in people with depression and anhedonia, the inability to experience pleasure or joy, which is a common symptom of many mental health conditions.

Sara Costi, Honorary Consultant at Oxford Health NHS Foundation Trust and Senior Clinical Researcher at the University of Oxford’s Department of Psychiatry co-led on the study.

Study participants were given either ezogabine or a placebo for five weeks and received MRI scans to assess activity in reward-related brain circuits. The results showed that ezogabine helped reduce brain activity related to anticipation and decreased connections between certain brain areas.

The article, “Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia”, published in Molecular Psychiatry, suggests that ezogabine might be useful in treating depression.

 

Read the story on the Department of Psychiatry website.